Dr. Franchimont has a background in rheumatology. Prior to her new role, she served as senior vice president and head of the multiple sclerosis and immunology development unit at Biogen.
“I am delighted to welcome Nathalie to our leadership team as Nimbus advances multiple potential breakthrough candidates into their next phase of development, including our clinical TYK2 and HPK1 inhibitors,” Nimbus CEO Jeb Keiper said in the Oct. 26 Nimbus news release.
